Format

Send to

Choose Destination
Cancer Res. 2019 Sep 1;79(17):4326-4330. doi: 10.1158/0008-5472.CAN-19-0803.

Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

Author information

1
Department of Oncology Gastrointestinal Cancer, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
2
Department of Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
3
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
4
Department of Surgery, Center for Translational Medicine, George Washington University, Washington D.C.
5
Department of Radiation Oncology, University of Toronto, Toronto, Ontario.
6
Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
7
Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, Universitat de Barcelona, Catalonia, Spain.
8
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.
9
Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Santa Monica, California.
10
Department of Environmental Health and Engineering, Epidemiology, Johns Hopkins, Bloomberg School of Public Health, Baltimore, Maryland.
11
Department of Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas.
12
Department of Pathology and Medicine, and Pittsburgh Liver Research Center, University of Pittsburgh, and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
13
Department of Human Carcinogenesis, NCI, Bethesda, Maryland.
14
Department of Pharmacology, University of California, San Diego School of Medicine, San Diego, California.
15
Department of Gastroenterology and Hepatology, Sanford I. Weill Medical College of Cornell University, New York, New York.
16
Department of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts.
17
Department of Medicine, Mayo Clinic, Rochester, Minnesota.
18
Department of Biology and Biochemistry, University of Houston, Houston, Texas.
19
Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.
20
Department of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, Michigan.
21
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
22
Department of Radiology, Feinberg School of Medicine, Chicago, Illinois.
23
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
24
Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
25
Department of Gastroenterology and Hepatology, VA Medical Center, Washington, D.C.
26
Department of Medicine and Oncology, Georgetown University, Lombardi Comprehensive Cancer Center, Washington, D.C.
27
Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio.
28
Janssen Research & Development, LLC, Titusville, New Jersey.
29
Department of Radiation Oncology, Pathology and Urology, Albert Einstein College of Medicine, Bronx, New York.
30
Division of Cancer Treatment and Diagnosis, Radiation Research Program, NCI, Rockville, Maryland. ahmedmm@mail.nih.gov norman.coleman@nih.gov.
31
Division of Cancer Treatment and Diagnosis, Molecular Radiation Therapeutics, Radiation Research Program, NCI, Rockville, Maryland. ahmedmm@mail.nih.gov norman.coleman@nih.gov.
#
Contributed equally

Abstract

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center